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With growing understanding of the underlying pathways of polyketide biosynthesis, alongwith the continual
expansion of the synthetic biology toolkit, it is becoming possible to rationally engineer and fine-tune the
polyketide biosynthetic machinery for production of new compounds with improved properties such as
stability and/or bioactivity. However, engineering the pathway to the thiomarinol antibiotics has proved
challenging. Here we report that genes from a marine Pseudoalternomonas sp. producing thiomarinol
can be expressed in functional form in the biosynthesis of the clinically important antibiotic mupirocin
from the soil bacterium Pseudomonas fluorescens. It is revealed that both pathways employ the same
unusual mechanism of tetrahydropyran (THP) ring formation and the enzymes are cross compatible.
Furthermore, the efficiency of downstream processing of 10,11-epoxy versus 10,11-alkenic metabolites
are comparable. Optimisation of the fermentation conditions in an engineered strain in which
production of pseudomonic acid A (with the 10,11-epoxide) is replaced by substantial titres of the more
stable pseudomonic acid C (with a 10,11-alkene) pave the way for its development as a more stable
antibiotic with wider applications than mupirocin.Introduction
Rapid acceleration in the emergence of antibiotic resistance in
pathogenic bacteria is severely eroding our ability to treat
bacterial infections.1 Central to an effective response to this
problem is the development of novel antibiotics with activity
against bacteria resistant to existing agents. A majority of
antibiotics in clinical use are natural products or their deriva-
tives, possessing chemotypes and properties oen lacking in
“drug-like” chemical libraries. Thus, rational engineering of
natural product biosynthetic pathways for production of new
compounds with improved stability and/or bioactivity is an
attractive route to overcoming resistance.2 However, the success
of such approaches requires detailed understanding of the
biosynthetic process.3
The antibiotic mupirocin produced by Pseudomonas uo-
rescens NCIMB 10586 is among the most effective topical
treatments for Gram-positive bacterial infections including
methicillin resistant Staphylococcus aureus (MRSA).4 It was
identied as one of the rst examples of the now extensive, Cantock's Close, BS8 1TS, Bristol, UK.
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tion (ESI) available. See DOI:
f Chemistry 2020family of antibiotics produced by the “trans-AT” class of
modular polyketides synthases (PKSs).5 Mupirocin is a mixture
of pseudomonic acids of which the major component (>90%,
Fig. 1) is pseudomonic acid A (1, PA-A) assembled on a C17-
polyketide derived moiety (monic acid) esteried by 9-hydrox-
ynonanoic acid (9-HN).6 Further minor components of mupir-
ocin include ca. 5% PA-B (2) containing an additional 8-hydroxyl
group and a minor product, <1%, PA-C (3), with a 10,11-alkene
rather than the 10,11-epoxide found in PA-A and PA-B. Studies
on mupirocin biosynthesis including analyses of wild-type and
mutant strains of P. uorescens and chemical complementation
studies have revealed that PA-B is formed rst and contains the
tetrahydropyran (THP) ring necessary for activity as shown in
Fig. 1A.7 The 8-OH is subsequently lost through a series of
transformations which begins with oxidation at C-6 to form
mupirocin P (4), requiring the enzymes MupU (CoA ligase),
MupO (P450), MacpE (acyl carrier protein, ACP) and MupV
(putative didomain oxidoreductase/thioesterase). Dehydration
(C7–C8) of 4 catalysed by MupP (dehydratase) followed by two
consecutive reductions by the oxidoreductases MupC (C6) and
MupF (C7) gives PA-A (1).8 PA-C (3) is the product of a minor
parallel pathway that branches from the main pathway (to PA-
A).9
A practical limitation of the major bioactive component, PA-
A, is that the 10,11-epoxide moiety renders the molecule
unstable outside a narrow pH range, due to formation of inac-
tive bicyclic products arising from attack of the 7-OH onto theChem. Sci., 2020, 11, 5221–5226 | 5221
Fig. 1 (A) Summary of the later stages of mupirocin biosynthesis showing the parallel pathways. (B) Structures of selected thiomarinols. (C)
Transformations of desepoxymupirocin P by the PKS mutant strain of Pseudoalteromonas SANK 73390.
























































































View Article Onlineepoxide.4 In contrast, the minor metabolite PA-C, containing
the 10,11-alkene, is much more stable. It is intriguing that in
wild-type P. uorescens 97% of total PAs and related metabolites
contain or are derived from a 10,11-epoxide whereas the parallel
minor biosynthetic pathway produces <3% of compounds with
the 10,11-alkene (e.g. PA-C). In contrast, the closely related thi-
omarinols (e.g. 7 and 8) all possess a 10,11-alkene (Fig. 1B).
The thiomarinols are a family of marine natural products
isolated from Pseudoalternomonas sp. SANK 73390 which also
exhibit potent antibiotic activity against MRSA.10 They are
assembled on a similar C17-polyketide moiety to the pseudo-
monic acids but differ in their esterication with an 8-hydrox-
yoctanoic acid (rather than 9-HN) side chain further linked as
an amide to a pyrrothine subunit of the holomycin class of
antibiotics. The major metabolite thiomarinol A (7) is also
hydroxylated at C-4. Labelling studies are in accord with a PKS/
NRPS origin of the thiomarinols.11 The mupirocin and thio-
marinol gene clusters show signicant homology but differ-
ences are evident.12 For example, homologues of the mupirocin
standalone ACP MacpE along with MupU and MupV, necessary
for conversion of PA-B to PA-A, are absent from SANK 73390.
TmpB however contains additional ketosynthase (KS) and ACP
domains as compared to MmpB, which are proposed to replace
the apparent missing activities.12
Compared with the mupirocin pathway which has been
readily modied,9 elucidating and engineering of the thiomar-
inol biosynthetic pathway in the marine organism has proved
remarkably challenging. So far, only the DtmlF, DtmlU, and the
mutant strains of Pseudoaltermonas sp. SANK 73390 in which
the PKS and NRPS parts of the gene cluster have been5222 | Chem. Sci., 2020, 11, 5221–5226deactivated have been successfully generated,8 all other gene
knock-out studies (e.g., DtmlW) have failed to produce any
isolable metabolites (unpublished results). Characterisation of
the family of metabolites, including 8-hydroxythiomarinol C (9)
(Fig. 1B) isolated from the DtmlF mutant of Pseudoaltermonas
sp. SANK 73390, combined with the processing of the THP ring
observed on feeding desepoxymupirocin P (6) to the PKSmutant
strain (Fig. 1C),8 indicates that it is likely that the late stage
biosynthetic machinery generating both thiomarinols and PAs
are closely related. However, details of the THP ring formation
in thiomarinol biosynthesis remains to be proven experimen-
tally. We now report in vitro functional characterisation of key
enzymes from the thiomarinol pathway and results from engi-
neering genes from the thiomarinol pathway into the mupir-
ocin system as well as a comparison of the processing efficiency
of 10,11-epoxy versus 10,11-alkenic metabolites at later stages of
the mupirocin biosynthetic pathway. Furthermore, by optimi-
sation of fermentation conditions, a signicant increase in
titres in cultures of mutants of P. uorescens producing PA-C as
the major metabolite has been achieved.Results
To investigate the apparent differences in metabolite ux
involving intermediates containing the 10,11-epoxide versus
10,11-alkenes, we focussed our investigations on two key parts
of the mupirocin biosynthetic pathway involving mid and late
stage transformations. The latter involves loss of the 8-OH going
from PA-B (2) to PA-A (1) whereas the mid-stage steps occur post
PKS-mediated backbone assembly and encompass 10,11-This journal is © The Royal Society of Chemistry 2020
























































































View Article Onlineepoxidation, THP ring formation and fatty acid chain extension
(Fig. 1A).
First to late stage processing: the conversion of desepoxy-PA-
B (5) to PA-C (3) (i.e. loss of the 8-hydroxyl group in metabolites
with the 10,11-alkene) was compared with the major pathway
involving PA-B with the analogous 10,11-epoxide. PA-B (2) was
isolated from cultures of the DmupU mutant of P. uorescens as
previously described.9 However, a new mutant was required to
access the corresponding 10,11-alkene, desepoxy-PA-B (5).
MmpEOR has been identied as the epoxidase9 and thus the
double mutant mmpEDOR/DmupU was generated and 5 was
isolated from fermentations of this strain (see ESI, Fig. S1†) in
similar titres to that obtained for PA-B from the DmupUmutant.
Two mutant strains, DmupA and DmupH, of P. uorescens
NCIMB 10586 were selected for the late stage mutasynthesis
studies as neither produce any metabolites assembled on 6,7-
dihydroxy-tetrahydropyrans.9 The same quantity of PA-B (2) and
desepoxy-PA-B (5) was fed to cultures of each of the mutants and
aer 2 days' growth, products were analysed by LC-MS by
comparison with standards for starting materials and products
(PA-A 1 and PA-C 3). Both substrates 2 (35% conversion) and 5
(75% conversion) were efficiently metabolised with overall loss
of the 8-OH to PA-A and PA-C respectively (Fig. 2). Thus the steps
involved in the removal of the 8-OH are not rate limiting in PA-C
production and so do not account for the signicantly different
titres of PAs and related metabolites containing a 10,11-epoxide
(97% of the total) compared with compounds with a 10,11-
alkene including PA-C (<3%) in wild-type P. uorescens.
Next, we turned to the mid-stage of mupirocin assembly and
the key step involving tetrahydropyran (THP) ring formation. It
has been shown previously that deletion of the oxygenase
MupW (or its redox partner MupT) abolished production of the
pseudomonic acids and led to accumulation of mupirocin W1
(14a) andW2 (14b) albeit in low titres.9,13 These metabolites lackFig. 2 (A) Comparison of the processing of the 8-OH-10,11-epoxy PA
(PA-B) with the analogous 10,11-alkene, desepoxy-PA-B. (B) HPLC
traces: Conversion of PA-B (2) to PA-A (1) by the DmupA and DmupH
mutants. (C) HPLC traces: Conversion of desepoxy-PA-B (5) to PA-C
(3) by the DmupA and DmupH mutants.
This journal is © The Royal Society of Chemistry 2020the THP ring but contain a new tetrahydrofuran ring and are
likely shunt products formed from the linear compounds 13a
and 13b which undergo spontaneous intra-molecular attack by
the 7-OH onto the 10,11-epoxide (Fig. 3A).13 Thus studies on
THP formation on substrates possessing the 10,11-epoxide
cannot be undertaken with linear substrates 13a/b. However,
using the corresponding 10,11-alkenes 15a/b isolated from the
mmpEDOR/DmupW strain we have recently shown that THP
formation occurs via an oxidative enzyme-catalysed cascade by
the dual action of the Rieske non-haem oxygenase MupW and
the epoxide hydrolase MupZ.14 Selective oxidation of the C8–C16
single bond in the acyclic precursors mupirocin W4 and W5
(15a/b) is proposed to give the corresponding 8,16-epoxide 16
(Fig. 3). In the absence of MupZ, the ve-membered tetrahy-
drofuran ring products mupirocin Z1 and Z2 (17a/b) were iso-
lated via spontaneous cyclisation (Fig. 3B).14
TmlW and TmlZ from the thiomarinol gene cluster, show
55.8% and 56.3% identity, respectively, to MupW and MupZ. To
investigate if the same mechanism of tetrahydropyran forma-
tion operates in both thiomarinol and mupirocin biosynthesis,
TmlW was heterologously overexpressed in E. coli which is able
to provide the additional redox partners and cofactors necessary
to constitute an active cascade.14 Linear substrate mupirocin
W5 (15b) was added to a whole-cell system using resting TmlW
overexpressing E. coli cells supplemented with glucose to enable
NAD(P)H regeneration (ESI†). LC-MS indicated full conversion
to a new product had occurred which on isolation and analysis
by NMR spectroscopy was conrmed to be tetrahydrofuran
mupirocin Z2 (17b), identical to that previously obtained from
the whole live cells of the MupW overexpressing E. coli strain
(Fig. S2†). Furthermore, incubation of mupirocin W4 (15a) with
E. coli cells overexpressing both MupW and TmlZ afforded the
THP ring product desepoxy-PA-B (5) (Fig. S2†). These results not
only conrm that thiomarinol biosynthesis employs the same
THP ring forming mechanism as that of mupirocin, but also
demonstrate that these enzymes are cross compatible.Fig. 3 (A) Structures of mupirocin W1 (14a) and W2 (14b) isolated from
the DmupW mutant of P. fluorescens. (B) THP ring formation in
mupirocin biosynthesis catalysed by the dual action of the Rieske non-
haem oxygenase MupW and the epoxide hydrolase MupZ.14 The
functions of their equivalents TmlW/TmlZ in thiomarinol biosynthesis
were confirmed in the present study.
Chem. Sci., 2020, 11, 5221–5226 | 5223
























































































View Article OnlineUnlike the major metabolites from wild-type P. uorescens
which contain the 10,11-epoxide, all thiomarinols isolated from
Pseudoalteromonas sp. SANK 73390 have a 10,11-alkene. Having
demonstrated MupW/TmlW and MupZ/TmlZ are functionally
interchangeable we therefore investigated if replacing mupW
with tmlW in the mupirocin gene cluster (Fig. 4A) would lead to
more efficient processing of 10,11-alkenes versus 10,11-epoxides
and hence alteration of the PA-C (3) to PA-A (1) ratio.
The entire mupW gene was rstly knocked out from the wild-
type strain of P. uorescens using the two-step allelic exchangeFig. 4 (A) Comparison of the mupirocin (mup) and thiomarinol (tml) bio
highlighted in red, mupW is replaced by tmlW to form the chimeric pat
allelic exchangemethod. (C) PCR identification of the knock-out and kno
tmlW mutants of P. fluorescens. (E) HPLC traces of the mmpEDOR
fluorescens.
5224 | Chem. Sci., 2020, 11, 5221–5226method (Fig. 4B).14,15 Desired mutants were screened by PCR
and conrmed by Sanger sequencing (Fig. 4C). The resulting
DmupW mutant produced only the THF-containing shunt
products mupirocin W1 and W2 (14a/b) (Fig. 4D). TmlW was
then introduced into the DmupW strain at the same locus from
which mupW was removed, using the same genetic manipula-
tion approach. This new hybrid mutant, P. uorescens DmupW-
tmlW, was cultured in parallel with the original wild-type P.
uorescens under the same fermentation conditions. This
restored PA-A production and the ratio of PA-C (trace) to PA-Asynthetic gene cluster, key genes involved in THP ring formation are
hway in this study. (B) Gene knock-out and knock-in by the two-step
ck-in mutants. (D) HPLC traces of the wild-type, DmupW and DmupW-
, mmpEDOR/DmupW and mmpEDOR/DmupW-tmlW mutants of P.
This journal is © The Royal Society of Chemistry 2020
Table 1 Minimum Inhibitory Concentration (MIC, mgmL1) of PA-A (1),
PA-B (2) and PA-C (3) against Gram-positive bacteria. Values were
obtained from microplate broth dilution
Strains PA-A (1) PA-B (2) PA-C (3)
Bacillus subtilis 0.06 1 <0.03
S. aureus ATCC 29213 0.125 4 0.25
S. aureus Newman 0.125 2 0.125
S. aureus NCTC 6571 0.125 2 0.125
S. aureus Mu50 0.125 2 0.125
S. epidermidis NCTC 11047 0.125 4 0.5
























































































View Article Online(major) in cultures of the mutant strain was equivalent to that
obtained for wild-type P. uorescens (Fig. 4D).
Next, the same knockout–knockin approach was applied to
the mmpEDORmutant of P. uorescens which only produces PA-
C. The mmpEDOR/DmupW mutant abolished PA-C production
and gave only the acyclic metabolites mupirocin W4 and W5
(15a/b) (Fig. 4E). The new hybrid mutant mmpEDOR/DmupW-
tmlW restored PA-C production, and titres were similar as
compared to mmpEDOR (Fig. 4E).
During our investigations we found that the titres of
mupirocin metabolites from both wild-type P. uorescens and
mutants were variable and hence we undertook a systematic
investigation to improve both the reproducibility and impor-
tantly the levels of metabolite production. Fermentation media,
incubation time and temperature, shaking speed etc. were
optimised for PA-C production. The key observation was that
when themmpEDORmutant was grown for 2 days at 22 C in LB-
broth supplemented with 4% glucose, the titres of PA-C (3)
reached a reproducible level of ca. 40 mg L1 in baffled asks
compared to ca. 2 mg L1 in unbaffled asks (Fig. 5 and S3†).
Minor metabolites isolated under these conditions include
a 4 : 1 mixture of desepoxy-PA-B (5) with mupirocin Z1 (17a)
(Fig. 5 and S4†), and the newly identied desepoxy-PA-D (19)
(Fig. 5, Table S1 and Fig. S5–S10†). The new hybrid mutant
mmpEDOR/DmupW-tmlW showed a similar result, again indi-
cating their equivalent effectiveness in initiating THP ring
formation. Interestingly, increased aeration during fermenta-
tion of cultures of mutants acting early in the pathway led to no
detectible differences in titres of accumulated acyclic interme-
diates such as 15a and 15b.
With signicant quantities of PA-C now available, antibiotic
activity screening of PA-C, along with PA-A and PA-B, against
a range of Gram-positive bacteria (Table 1) was undertaken. TheFig. 5 HPLC trace of the mmpEDOR mutant cultured in baffled flasks c
This journal is © The Royal Society of Chemistry 2020more chemically stable PA-C (3) exhibited comparable antibi-
otic activity to PA-A, with, notably, similar activity against the
four Staphylococcus aureus strains tested, including the Mu50
strain that both exhibits a methicillin-resistant (MRSA) pheno-
type and reduced susceptibility to glycopeptides including
vancomycin. These data conrm the effectiveness of monic
acid-based agents against Gram-positive pathogens, including
strains challenging to treat with rst-line antibiotics, and that
antibacterial activity is not adversely affected by substitution of
the 10,11-epoxide of mupirocin for the 10,11-alkene. Notably,
PA-B displayed substantially lower activity in all susceptibility
assays. As PA-B and desepoxy-PA-B are normally intermediates
towards the mature antibiotics PA-A and PA-C, respectively, this
may be of physiological signicance in terms of self-resistance.Conclusions and discussion
In conclusion we have demonstrated that the late-stage pro-
cessing in mupirocin biosynthesis of the 10,11-alkene is as
efficient as the 10,11-epoxide and that transformations leading
to the removal of the 8-hydroxyl groups do not account for theompared to in unbaffled flasks.
Chem. Sci., 2020, 11, 5221–5226 | 5225
























































































View Article Onlinevery different levels of PA-A and PA-C production in WT P. u-
orescens. Epoxidation catalysed by MmpE is presumably very
efficient. The mupirocin pathway was engineered with heterol-
ogous genes from the thiomarinol pathway thereby demon-
strating that genes from the marine organism
Pseudoalternomonas sp. SANK 73390 can be expressed in func-
tional form in the soil bacterium P. uorescens. Furthermore, it
is revealed that both pathways employ the same unusual
mechanism of tetrahydropyran (THP) ring formation and that
the enzymes responsible for this activity are cross compatible.
Whilst the mupirocin and thiomarinol gene clusters show
high homology, there are signicant differences.12 Genetic
engineering of the thiomarinol pathway in the marine organism
has, however, proved remarkably difficult (only four mutants
have been reported to date8), leading to signicant challenges in
elucidating the biosynthesis of these marine natural products.
We envisage that heterologous expression of components from
the thiomarinol pathway in themupirocin producer will provide
an alternative approach elucidating their biosynthesis.
Access to engineered strains of P. uorescens in which the
major product is the more stable PA-C, rather than PA-A in wild
type, has potential for industrial scale production of PA-C and
subsequent further development as a more stable antibiotic
with wider applications than mupirocin.
The plug-and-play approach for the assembly of heterolo-
gous genes in the mupirocin biosynthetic gene cluster will be
useful for further engineering of polyketide biosynthesis. By
building on existing polyketide engineering and character-
isation strategies, harnessing current synthetic biology tech-
nologies, and utilising advances in metabolic/host engineering,
we anticipate future successes in engineering PKSs capable of
producing designer polyketides for applications in medicine,
fuels, and industrial products.16
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